The mechanism of non biological artificial liver "DPMAES+PDF" regulating liver cell regeneration through the "CSS/MD" signaling pathway in chronic and acute liver failure

Study on the Mechanism of Bu Gan Sheng Sheng Tang Combined with Artificial Liver "DPMAES+PDF" in Regulating Liver Cell Regeneration through the "CSS/MD" Signal Pathway in Chronic Acute Liver Failure Based on the Theory of Xianghuo Sheng Fa

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076571

Enrollment

Unknown

Registered

2023-10-12

Start date

2023-05-18

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute-on-chronic liver failure

Interventions

Observation group:The observation group was treated with artificial liver "DPMAES+PDF" mode and "Bugan Shengsheng Tang" orally

All patients received comprehensive support treatment from the internal medicine department, with a treatment course of 2 weeks.

Control group1:The control group 1 received artificial liver "DPMAES+PDF" mode treatment, and all received comprehensive medical support treatment, with a treatment course of 2 weeks.

Control group2:Control group 2 was given "DPMAE+Bugan Shengsheng Tang" orally

Received comprehensive support treatment from the internal medicine department, with a treatment course of 2 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Inclusion criteria: Patients who sign an informed consent form and are between the ages of 18 and 65, regardless of gender; ? Meets the diagnostic criteria of ACLF in the 2018 "Guidelines for the Diagnosis and Treatment of Liver Failure", including type A, B, or C; ? Staging belongs to the early, early, or mid-term clinical diagnostic criteria; ? The disease is caused by hepatitis B.

Exclusion criteria

Exclusion criteria: ? Co infection with human immunodeficiency virus (HIV); ? Malignant tumors; ? Acute attacks of cardiovascular and cerebrovascular diseases; ? Combined renal failure; ? Pregnant and lactating women; ? Mental illness patients; ? Severe active bleeding or disseminated intravascular coagulation; ? Highly allergic to blood products or drugs used during the treatment process, such as plasma and heparin; ? Circulatory failure; ? Patients with unstable stage of myocardial infarction; ? Late pregnancy

Design outcomes

Primary

Measure	Time frame
Survival rate;AFP;PTA;TBIL;Endotoxin;	—

Secondary

Measure	Time frame
TNFa;IFN?;IL-6;IL-17;IL-1;IL-10;CRP;PCT;Fatty acyl Coa dehydrogenase, adenosine translocation protein, mitochondrial MPT protein;ATP7B gene, Cytoc gene, KAT2B gene rs17006625 locus gene;lactic acid;Lung and upper abdomen CT;MELD ;	—

Countries

China

Contacts

Public ContactXianwen Cheng

Ankang Traditional Chinese Medicine Hospital Affiliated to Shaanxi University of Traditional Chinese Medicine

807497738@qq.com+86 177 7292 8900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026